Andrew Shoffstall, PhD | CSO
Dr. Shoffstall is Co-Founder and Chief Scientific Officer at Neuronoff, Inc.
Prior to co-founding Neuronoff, he worked as Senior Analyst at Health Advances, a healthcare strategy consulting firm near Boston, MA. His work focused on scientific and market due diligence applied in projects ranging from life sciences to pharmaceutical, diagnostics, and medical device companies to provide independent third party evaluation of product market size, M&A target identification, R&D and private grant funding portfolio prioritization, pricing, and reimbursement analysis.
Outside of Neuronoff, Dr. Shoffstall is an Assistant Professor in the department of Biomedical Engineering at Case Western Reserve University and holds a secondary appointment as Biomedical Engineer at the APT Center at the Louis Stokes Cleveland VA Medical Center. His primary areas of research focus on the development of minimally invasive neural interfaces for lower risk, lower cost, and higher impact applications in neuromodulation. His has several funded research programs related to: 1) novel electrodes for neural stimulation and recording (including Neuronoff’s Injectrode), 2) platelet-inspired therapeutics to reduce neuroinflammation in the brain, 3) elucidating the anatomical organization of autonomic nerves to maximize neuromodulatory stimulation treatments, and 4) evaluation of the tissue response to implanted neural devices. As part of his work, he considers the impact that manufacturability, scalability, sterilization, cost-of-goods, regulatory, reimbursement, supply chain and sourcing have on the success of a new technology or therapy.
In 2022, Dr. Shoffstall received a $15.75mm grant from the NIH SPARC REVA program to map the vagus nerve to ultimately inform new treatment options for conditions such as hypertension, heart failure and gastrointestinal disorders, as a better understanding of the underlying anatomical organization of the nervous system has the potential to improve the precision of neuromodulation. In 2021, Dr. Shoffstall became PI of a $500k Ohio 3rd Frontier Spinal Cord Injury Research Incentive grant to study an “Injectable multi-level sacral root neuromodulation interface for the treatment of SCI bladder dysfunction”. The project is focused on the feasibility, efficacy and safety evaluation of the Injectrode for sacral neuromodulation.
Dr. Shoffstall graduated with his PhD from Case Western Reserve University, developing an expertise in materials science, engineering of optimized tissue interfaces and translational development work. He holds a BS in Biological and Environmental Engineering from Cornell University.